NCT00191503View on ClinicalTrials.gov

Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2005

Study Completion Date

November 30, 2005

Conditions
Adenocarcinoma
Interventions
DRUG

Pemetrexed

DRUG

Gemcitabine

Trial Locations (2)

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Calgary

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Edmonton

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00191503 - Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma | Biotech Hunter | Biotech Hunter